Ropivacaine Fresenius Kabi

What Is Ropivacaine Fresenius Kabi and What Is It Used For?

Ropivacaine Fresenius Kabi contains the active substance ropivacaine hydrochloride, a member of the amide-type local anesthetic family. Local anesthetics work by temporarily blocking nerve conduction, preventing pain signals from reaching the brain. Unlike general anesthesia, which renders the entire body unconscious, local anesthetics like ropivacaine target specific regions, allowing patients to remain awake during procedures while experiencing pain relief in the affected area.

The 2 mg/ml infusion solution is specifically formulated for continuous administration and is used primarily for acute pain relief, most commonly in the postoperative setting. It is administered as an infusion – a slow, controlled delivery of the medication into targeted anatomical regions. This approach provides sustained analgesia that can last from 30 minutes to up to 72 hours depending on the clinical situation and administration technique.

Ropivacaine is a pure S-enantiomer, which contributes to its favorable pharmacological profile. Compared to the closely related drug bupivacaine (a racemic mixture), ropivacaine demonstrates a wider margin of safety with regard to central nervous system and cardiovascular toxicity. This is a key clinical advantage, particularly for continuous epidural infusions where larger cumulative doses are administered over extended periods.

The medication is approved for use in both adults and children of all ages for postoperative and acute pain management. In clinical practice, it is commonly used for epidural analgesia following abdominal, thoracic, and orthopedic surgeries, as well as for peripheral nerve blocks. The ability to provide effective sensory blockade while relatively sparing motor function makes ropivacaine particularly useful when early mobilization is an important part of the patient's recovery plan, as outlined in enhanced recovery after surgery (ERAS) protocols recommended by the European Society of Regional Anaesthesia and Pain Therapy (ESRA).

What Should You Know Before Taking Ropivacaine Fresenius Kabi?

Contraindications

There are specific situations in which Ropivacaine Fresenius Kabi must not be used. Understanding these contraindications is essential for safe administration. You must not be given this medication if:

• You are allergic (hypersensitive) to ropivacaine hydrochloride or any of the other ingredients in the formulation (listed in the composition section below).
• You are allergic to other amide-type local anesthetics, such as lidocaine or bupivacaine. Cross-reactivity within the amide class is well-documented, and patients with a known allergy to one amide-type agent should avoid all others in this class.
• You have been told you have low blood volume (hypovolemia). Administering ropivacaine to hypovolemic patients significantly increases the risk of severe hypotension and cardiovascular collapse.
• The medication is intended for intravenous regional anesthesia (Bier block). Ropivacaine should never be injected directly into a blood vessel for this purpose.
• The medication is intended for paracervical block in obstetrics. This specific application is contraindicated due to the risk of fetal bradycardia.

Warnings and Precautions

Before receiving Ropivacaine Fresenius Kabi, it is essential to discuss your complete medical history with your healthcare team. Certain conditions may require dose adjustments or additional monitoring during and after administration.

Tell your doctor, nurse, or other healthcare professional before being given Ropivacaine Fresenius Kabi if:

• Your general health is poor due to age or other factors. Elderly patients and those with significant comorbidities may be more susceptible to the systemic effects of local anesthetics and may require reduced doses.
• You have heart problems, particularly partial or complete atrioventricular (AV) block. Ropivacaine, like all amide-type local anesthetics, can affect cardiac conduction, and pre-existing conduction abnormalities increase the risk of serious cardiac events.
• You have severe liver disease. Ropivacaine is primarily metabolized in the liver by cytochrome P450 enzymes (mainly CYP1A2 and CYP3A4). Severe hepatic impairment can significantly reduce clearance, leading to higher plasma levels and increased risk of toxicity.
• You have severe kidney disease. Although renal excretion of unchanged ropivacaine is minimal, metabolite accumulation may occur in patients with severely impaired kidney function.
• You suffer from acute porphyria, a condition involving problems with the production of red blood pigment that can cause neurological symptoms. If you or a family member has porphyria, a different anesthetic agent may be needed, as amide-type local anesthetics may be porphyrinogenic.

Use in Children

Special care should be taken when administering Ropivacaine Fresenius Kabi 2 mg/ml to pediatric patients. Neonates are particularly susceptible to the effects of ropivacaine because their immature hepatic enzyme systems result in slower drug metabolism. Plasma levels may remain elevated for longer periods in this population, increasing the risk of systemic toxicity.

For children under 12 years of age, certain administration techniques with Ropivacaine Fresenius Kabi 2 mg/ml for regional nerve blocks have not been established in clinical trials. Dosing in pediatric patients must be carefully calculated based on body weight, and continuous monitoring is essential throughout the procedure and recovery period.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before this medicine is administered to you. The effects of ropivacaine during pregnancy have not been fully established through controlled clinical studies. It is also not known whether ropivacaine is excreted in breast milk. Your physician will carefully assess the potential benefits against possible risks before deciding whether to use this medication during pregnancy or lactation.

While ropivacaine is widely used for epidural analgesia during labor and cesarean section, this specific low-concentration infusion formulation (2 mg/ml) is primarily intended for postoperative pain management rather than obstetric analgesia. The decision to use ropivacaine in pregnant or breastfeeding women should always be made by a qualified healthcare professional who can evaluate the individual clinical situation.

Driving and Operating Machinery

Ropivacaine Fresenius Kabi may cause drowsiness and can affect reaction times and coordination. You should not drive, operate heavy machinery, or engage in activities requiring alertness until the day after receiving the medication. You are personally responsible for assessing whether you are fit to drive or perform tasks that require concentration. The effects of local anesthesia on specific body regions, combined with potential systemic effects such as dizziness, may impair your ability to perform these activities safely.

How Does Ropivacaine Fresenius Kabi Interact with Other Drugs?

Drug interactions with ropivacaine can occur through two main mechanisms: additive pharmacological effects (when combined with other drugs that affect nerve conduction or cardiovascular function) and pharmacokinetic interactions (when other drugs alter the metabolism or elimination of ropivacaine). Understanding these interactions is critical for safe administration and optimal dosing.

Tell your doctor or healthcare professional about all medications you are taking, have recently taken, or may take. This includes prescription medicines, over-the-counter drugs, vitamins, and herbal supplements. Your physician needs this information to determine the correct dose and monitor for potential complications.

Major Interactions

The following drug classes can significantly affect the safety and efficacy of ropivacaine and require particular attention:

Minor Interactions and Compatibility

Ropivacaine Fresenius Kabi infusion solution (1–2 mg/ml) has been shown to be chemically and physically compatible with the following adjuvant medications when mixed in the infusion bag:

These mixtures are chemically and physically stable for 30 days at 20–30°C. However, from a microbiological standpoint, the mixtures should be used immediately after preparation. If not used immediately, storage should generally not exceed 24 hours at 2–8°C.

What Is the Correct Dosage of Ropivacaine Fresenius Kabi?

Ropivacaine Fresenius Kabi will always be administered by a qualified physician or under the direct supervision of a physician experienced in regional anesthesia. The medication is never self-administered. Your doctor will determine the appropriate dose based on several factors including the type of anesthesia or analgesia required, the anatomical site of administration, your body weight, age, and overall health status.

The medication is given as a controlled infusion into one of the following anatomical sites, depending on the clinical indication:

• The area to be numbed – for local wound infiltration and field blocks.
• Near the nerves serving the target area – for peripheral nerve blocks (e.g., brachial plexus, femoral nerve).
• The epidural space (around the spinal cord) – for epidural infusions providing broad regional analgesia.

When ropivacaine is administered at any of these sites, it blocks nerve impulses from being transmitted to the brain. This prevents sensations of pain, heat, and cold in the targeted area, while other sensations such as pressure and touch may still be partially preserved – a phenomenon known as differential blockade, which is a characteristic advantage of ropivacaine.

Adults

Children

Elderly Patients

Overdose

Serious adverse effects from receiving too much ropivacaine require immediate specialized medical intervention. Your physician is trained to recognize and manage these emergencies. The earliest signs of ropivacaine overdose typically include:

• Hearing and vision problems
• Numbness of the lips, tongue, and around the mouth
• Dizziness and light-headedness
• Tingling sensations
• Speech difficulties (dysarthria)
• Muscle stiffness and muscle twitching
• Seizures (convulsions)
• Low blood pressure
• Slow or irregular heartbeat

What Are the Side Effects of Ropivacaine Fresenius Kabi?

Like all medicines, Ropivacaine Fresenius Kabi can cause side effects, although not everybody gets them. The likelihood and severity of side effects depend on the dose administered, the site of injection, and individual patient factors. Most side effects are related to the pharmacological mechanism of action and are generally manageable when the drug is administered by experienced healthcare professionals in an appropriate clinical setting.

Allergic Reactions

Sudden life-threatening allergic reactions (anaphylaxis) are rare (may affect up to 1 in 1,000 people). Symptoms may include sudden onset of rash, itchy or bumpy hives, swelling of the face, lips, tongue, or other body parts, shortness of breath, wheezing, or difficulty breathing, and a feeling of losing consciousness. If you suspect an allergic reaction, tell your doctor or healthcare professional immediately.

Side Effects by Frequency

Other Reported Side Effects

The following side effects have been reported with an unknown frequency:

• Horner's syndrome – characterized by reduced pupil size, drooping upper eyelid, and decreased sweating on the affected side of the face. This can occur with epidural administration, particularly in pregnant women. The condition resolves spontaneously when treatment is discontinued.
• Involuntary muscle movements (dyskinesia)
• Numbness due to nerve irritation caused by the needle or injection – this is usually temporary and self-limiting.

Some symptoms may occur if the injection is accidentally given into a blood vessel or if too much ropivacaine is administered. These include seizures, dizziness, numbness of the lips and around the mouth, numbness of the tongue, hearing problems, vision problems, speech difficulties, muscle stiffness, and tremors.

Side Effects in Children

In children, the side effects are generally the same as in adults, with two notable differences:

• Low blood pressure occurs less frequently in children (may affect up to 1 in 10 children, compared to more than 1 in 10 adults).
• Vomiting occurs more frequently in children (may affect more than 1 in 10 children).

If an epidural injection is given (into the space around the spinal nerves), it can potentially cause disturbances in a nerve pathway from the brain to the head and neck. In rare cases, particularly in pregnant women, this may result in total spinal anesthesia, where the entire body becomes numb. This is a medical emergency that requires immediate intervention.

How Should You Store Ropivacaine Fresenius Kabi?

Ropivacaine Fresenius Kabi is typically stored and managed by your doctor or the hospital pharmacy. However, the following storage guidelines apply to ensure product integrity and safety:

• Keep out of sight and reach of children.
• Do not use after the expiry date printed on the bag and outer carton after “EXP.” The expiry date refers to the last day of the indicated month.
• Store at or below 30°C. No special refrigeration is required under normal conditions.
• Do not use if precipitation or particulate matter is visible in the infusion solution. The solution should be clear and colorless.
• This product is for single use only. Any remaining solution after use must be discarded.
• Do not re-autoclave intact containers.
• When a sterile outer surface is required, use a bag with an intact overwrap.

The medication should not be disposed of via wastewater or household waste. Your doctor, nurse, or pharmacist will ensure that unused medicine is disposed of according to applicable environmental regulations. These measures help protect the environment and prevent accidental exposure.

What Does Ropivacaine Fresenius Kabi Contain?

Active Ingredient

The active substance is ropivacaine hydrochloride 2 mg/ml.

• A 100 ml bag contains 200 mg ropivacaine hydrochloride.
• A 200 ml bag contains 400 mg ropivacaine hydrochloride.

Inactive Ingredients (Excipients)

The other ingredients are:

• Sodium chloride – for isotonicity adjustment
• Hydrochloric acid – for pH adjustment
• Sodium hydroxide – for pH adjustment
• Water for injections – solvent

Appearance and Pack Sizes

Ropivacaine Fresenius Kabi 2 mg/ml solution for infusion is a clear, colorless solution supplied in transparent plastic bags. It is available in the following pack sizes:

• 1 bag with overwrap
• 5 bags with overwrap
• 10 bags with overwrap

Not all pack sizes may be marketed in every country.

Manufacturer

Ropivacaine Fresenius Kabi is manufactured by Halden Pharma AS (Halden, Norway) and marketed by Fresenius Kabi AB (Uppsala). Fresenius Kabi is a global healthcare company specializing in clinical nutrition and infusion therapy, with operations in more than 60 countries worldwide.